Anthropic AI Model Uncovers Vulnerabilities in Classified U.S. Government Systems During Security Test 
WiseTech Global Denies Knowledge of Investigation Into Founder Richard White 
Tencent Reviews Marvelous Stake as Gaming Giant Reassesses Global Investment Strategy 
Bain Capital Nears Deal for Majority Stake in Volkswagen Marine Engine Unit Everllence 
Alphabet Replaces Verizon in Dow Jones Industrial Average 
DOJ Opens Investigation Into NYC Coffee Shop Over Anti-Goldman Social Media Post 
SK Hynix Targets $29.4 Billion Nasdaq Listing to Expand AI Chip Business 
KPMG Australia Chairman and Senior Partners Exit Amid Escalating Whistleblower Scandal 
Ryan Cohen Rejects GameStop Pay Package, Prepares New eBay Acquisition Plan 
Heineken Names JDE Peet’s CEO Rafael Oliveira as New Chief Executive 
Tesla and NatPower Partner on $5 Billion Battery Storage Expansion in Europe 
Doncasters Raises $919 Million in NYSE IPO as Aerospace Growth Accelerates 
Pelosi Discloses Major Intel and Uber Call Option Purchases Worth Up to $6 Million 
Meta Reportedly Developing ‘Arena’ Prediction Market App to Rival Polymarket and Kalshi 
Micron Stock Surges on Strong AI Demand, Record Revenue, and Bullish Q4 Forecast 
Cerebras Revenue Forecast Tops Expectations, but Margin Concerns Weigh on Stock 
Samsung Electronics Stock Surges on Report of Massive $59 Billion Share Buyback Plan 
SANTA MONICA, Calif., Feb. 24, 2016 -- Kite Pharma, Inc., (Nasdaq:KITE) today announced that it will report fourth quarter and full year 2015 financial results on Monday, February 29, 2016 after market close, and will host a conference call to discuss financial results and provide a business update at 4:30 PM Eastern Time (1:30 PM Pacific Time).
Audio Webcast
Interested parties may access a live audio webcast of the conference call on the Investors section of Kite’s website, www.kitepharma.com. A replay of the webcast will be available on the website for approximately 30 days.
Dial-In Information
Live (U.S. / Canada): (877) 301-8565
Live (International): (678) 562-4240
Confirmation number: 45173015
About Kite Pharma
Kite Pharma, Inc., is a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a primary focus on engineered autologous cell therapy (eACT™) designed to restore the immune system's ability to recognize and eradicate tumors. Kite is based in Santa Monica, CA. For more information on Kite Pharma, please visit www.kitepharma.com. Sign up to follow @KitePharma on Twitter at www.twitter.com/kitepharma.
CONTACT: Greg Mann VP, Investor Relations [email protected] For Media: Justin Jackson Burns McClellan (212) 213-0006 [email protected]
